100 related articles for article (PubMed ID: 23474009)
21. Pre-medications for cetuximab induced infusion reactions - commentary.
McKibbin T; Donald Harvey R; Saba NF
Oral Oncol; 2014 Dec; 50(12):e71. PubMed ID: 25223595
[No Abstract] [Full Text] [Related]
22. Cetuximab in squamous cell carcinoma of the head and neck.
Hitt R; Martín P; Hidalgo M
Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
[TBL] [Abstract][Full Text] [Related]
23. Response to: 'Pre-medications for cetuximab induced infusion reactions - commentary'.
Adkins D; Ley J
Oral Oncol; 2014 Dec; 50(12):e72. PubMed ID: 25282254
[No Abstract] [Full Text] [Related]
24. Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer.
Lee SS; Chu PY
Am J Otolaryngol; 2010; 31(4):288-90. PubMed ID: 20015761
[TBL] [Abstract][Full Text] [Related]
25. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
26. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
[TBL] [Abstract][Full Text] [Related]
27. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
[TBL] [Abstract][Full Text] [Related]
28. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
29. Effects of the administration of epidermal growth factor receptor specific inhibitor cetuximab, alone and in combination with cisplatin, on proliferation and apoptosis of Hep-2 laryngeal cancer cells.
Bussu F; Pozzoli G; Giglia V; Rizzo D; Limongelli A; De Corso E; Graziani C; Paludetti G; Navarra P; Almadori G
J Laryngol Otol; 2014 Oct; 128(10):902-8. PubMed ID: 25236402
[TBL] [Abstract][Full Text] [Related]
30. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
31. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
Teoh DC; Rodger S; Say J; Hartley A
Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
[No Abstract] [Full Text] [Related]
32. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.
Burtness B
J Clin Oncol; 2005 Aug; 23(24):5440-2. PubMed ID: 16009959
[No Abstract] [Full Text] [Related]
33. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
[TBL] [Abstract][Full Text] [Related]
34. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results.
Balermpas P; Keller C; Hambek M; Wagenblast J; Seitz O; Rödel C; Weiss C
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e377-83. PubMed ID: 22414284
[TBL] [Abstract][Full Text] [Related]
35. [Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell cancer].
Vladimirova LY; Agieva AA; Engibaryan MA
Vopr Onkol; 2015; 61(4):580-2. PubMed ID: 26571826
[TBL] [Abstract][Full Text] [Related]
36. Treatment of advanced head and neck cancer with cetuximab.
Merlano M; Garrone O
Int J Biol Markers; 2007; 22(1 Suppl 4):S71-6. PubMed ID: 17520584
[TBL] [Abstract][Full Text] [Related]
37. Nephrotic syndrome induced by cetuximab in a patient with metastatic colorectal cancer.
Korkmaz M; Hendem E; Karakurt Eryılmaz M; Demirkıran A; Karaağaç M; Artaç M
J Oncol Pharm Pract; 2022 Jun; 28(4):998-1002. PubMed ID: 35023411
[TBL] [Abstract][Full Text] [Related]
38. Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report.
Ismail I; Nigam S; Parnham A; Srinivasa V
J Med Case Rep; 2017 Aug; 11(1):214. PubMed ID: 28779751
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
40. 18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.
Hoeben BA; Troost EG; Bussink J; van Herpen CM; Oyen WJ; Kaanders JH
Nuklearmedizin; 2014; 53(2):60-6. PubMed ID: 24468965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
